Skip to main content
Log in

Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1–3 October 2009

  • Meeting Report
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abbreviations

ACT:

Adoptive cell therapy

APC:

Antigen-presenting cells

AS:

Adjuvant system

CIK:

Cytokine-induced killer

COA:

Colon antigen

CRC:

Colorectal cancer

CSC:

Cancer stem cells

CTC:

Circulating tumor cells

CTL:

Cytotoxic T lymphocytes

CTLA-4:

Cytotoxic T lymphocyte-associated antigen-4

CTX:

Cyclophosphamide

DC:

Dendritic cells

DXR:

Doxorubicin

HDI:

High-dose interferon-alpha-2b

IDO:

Indoleamine 2,3-dioxygenase

IFN:

Interferon

IL:

Interleukin

mAb:

Monoclonal antibody

MM:

Metastatic melanoma

NB:

Neuroblastoma

NGR:

Asn-Gly-Arg

NHL:

Non-Hodgkin lymphoma

NK:

Natural killer

PC:

Pancreatic cancer

PTPRK:

Protein tyrosine phosphatase receptor kappa

TAA:

Tumor-associated antigen

TERT:

Telomerase reverse transcriptase

TRAMP:

Transgenic adenocarcinoma mouse prostate

Tregs:

Regulatory T cells

Acknowledgments

This work was supported in part by grants from Associazione Italiana per la Ricerca sul Cancro and Alleanza Contro il Cancro.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Michele Maio.

Additional information

The collaborators of NIBIT are given in the appendix.

Appendix: Collaborators

Appendix: Collaborators

Paola Allavena, Istituto Clinico Humanitas IRCCS, Rozzano (MI), Italy;

Andrea Anichini, National Cancer Institute, Milan, Italy;

Matteo Bellone, San Raffaele Scientific Institute, Milan, Italy;

Vincenzo Bronte, Istituto Oncologico Veneto, Padua, Italy;

Luana Calabrò, University Hospital of Siena, Siena, Italy;

Chiara Camisaschi, National Cancer Institute, Milan, Italy;

Chiara Castelli, National Cancer Institute, Milan, Italy;

Angelo Corti, San Raffaele Scientific Institute, Milan, Italy;

Marco Danova, San Matteo Hospital, Pavia, Italy;

Paolo Dellabona, San Raffaele Scientific Institute, Milan, Italy;

Anna Maria Di Giacomo, University Hospital of Siena, Siena, Italy;

Massimo Di Nicola, National Cancer Institute, Milan, Italy;

Guido Ferlazzo, University of Messina, Messina, Italy;

Giusy Gentilcore, National Cancer Institute, Naples, Italy;

Leonardo Giovannoni, Philogen, Siena, Italy;

Patrick Hwu, M.D. Anderson Cancer Center, Houston, USA;

Frederic Lehmann, GlaxoSmithKline, Rixensart, Belgium;

Cristina Maccalli, San Raffaele Scientific Institute, Milan, Italy;

Ignacio Melero, University of Navarra, Pamplona, Spain;

Vladia Monsurrò, University of Verona, Verona, Italy;

Daniela Montagna, Fondazione IRCCS, Policlinico San Matteo, University of Pavia, Pavia, Italy;

Federica Moschella, Istituto Superiore di Sanità, Rome, Italy;

Mirco Ponzoni, Gaslini Children’s Hospital, Genoa, Italy;

Maria Pia Protti, San Raffaele Scientific Institute, Milan, Italy;

Paolo Puccetti, University of Perugia, Perugia, Italy;

Dario Sangiolo, Institute for Cancer Research and Treatment, Turin, Italy;

Gerold Schuler, University Hospital of Erlangen, Erlangen, Germany.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maio, M., Nicolay, H.J.M., Ascierto, P.A. et al. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1–3 October 2009. Cancer Immunol Immunother 59, 1895–1901 (2010). https://doi.org/10.1007/s00262-010-0832-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-010-0832-2

Keywords

Navigation